These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22928785)

  • 21. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.
    Di Lorenzo G; Buonerba C; Faiella A; Rescigno P; Rizzo M; Autorino R; Perdonà S; Riccardi N; Scagliorini S; Scognamiglio F; Masala D; Ferro M; Palmieri G; Aieta M; Marinelli A; Altieri V; De Placido S; Cartenì G
    BJU Int; 2011 Jan; 107(2):234-9. PubMed ID: 20590545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
    Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
    Cohen RB; Jones SF; Aggarwal C; von Mehren M; Cheng J; Spigel DR; Greco FA; Mariani M; Rocchetti M; Ceruti R; Comis S; Laffranchi B; Moll J; Burris HA
    Clin Cancer Res; 2009 Nov; 15(21):6694-701. PubMed ID: 19825950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
    Borthakur G; Dombret H; Schafhausen P; Brummendorf TH; Boissel N; Jabbour E; Mariani M; Capolongo L; Carpinelli P; Davite C; Kantarjian H; Cortes JE
    Haematologica; 2015 Jul; 100(7):898-904. PubMed ID: 25887498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
    Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
    Beer TM; Ryan C; Alumkal J; Ryan CW; Sun J; Eilers KM
    Anticancer Drugs; 2010 Apr; 21(4):433-8. PubMed ID: 20016365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial.
    Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Valduga F; Cetto G; Galligioni E
    BJU Int; 2008 Nov; 102(9):1080-5. PubMed ID: 18485028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
    Sonpavde G; Aparicio AM; Zhan F; North B; Delaune R; Garbo LE; Rousey SR; Weinstein RE; Xiao L; Boehm KA; Asmar L; Fleming MT; Galsky MD; Berry WR; Von Hoff DD
    Urol Oncol; 2011; 29(6):682-9. PubMed ID: 19959380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
    Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD
    J Clin Oncol; 2004 Jul; 22(13):2532-9. PubMed ID: 15226321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
    Takaha N; Okihara K; Kamoi K; Hongo F; Iwata T; Yano K; Ueda T; Takeuchi I; Yamada T; Kawauchi A; Miki T
    Urol Int; 2011; 87(3):263-9. PubMed ID: 21876321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
    Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V
    Cancer; 2008 Apr; 112(7):1455-61. PubMed ID: 18300256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
    Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
    Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study.
    Caffo O; Fratino L; Barbieri R; Perin A; Martini T; Sava T; Segati R; Vaccher E; Bernardo Bassan F; Veccia A; Pappagallo G; Galligioni E
    Urol Oncol; 2013 Feb; 31(2):180-6. PubMed ID: 21803618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peg-filgrastim and cabazitaxel in prostate cancer patients.
    Di Lorenzo G; DʼAniello C; Buonerba C; Federico P; Rescigno P; Puglia L; Ferro M; Bosso D; Cavaliere C; Palmieri G; Sonpavde G; De Placido S
    Anticancer Drugs; 2013 Jan; 24(1):84-9. PubMed ID: 23044721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer.
    Chadha MK; Ashraf U; Lawrence D; Tian L; Levine E; Silliman C; Escott P; Payne V; Trump DL
    Prostate; 2008 Sep; 68(13):1461-6. PubMed ID: 18618738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.